Basic Information
| LncRNA/CircRNA Name | ADAMTS9-AS2 |
| Synonyms | lncADAMTS9-AS2 |
| Region | GRCh38_3:64684909-65011468 |
| Ensemble | ENSG00000241684 |
| Refseq | NR_038264 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, RNAi, other |
| Sample | OC tissues and cell lines (SKOV3, HO8910, A2780, OVCAR, and HOSEpiC |
| Expression Pattern | down-regulated |
| Function Description | Low ADAMTS9-AS2 expression was correlated with advanced FIGO stage, lymph-node metastasis, and poor overall survival of OC patients. Function assays showed that ADAMTS9-AS2 reduced OC cells proliferation, invasion, and epithelial-mesenchymal transition (EMT) processes in vitro and restrained tumor growth in vivo. The underlying mechanism studies indicated that ADAMTS9-AS2 functioned as a competing endogenous RNA (ceRNA) for miR-182-5p to promote cell proliferation and invasion. In addition, we revealed that FOXF2 acted as a direct target of miR-182-5p and mediated the effects of ADAMTS9-AS2 on OC cells progression. |
| Pubmed ID | 30268751 |
| Year | 2018 |
| Title | LncRNA ADAMTS9-AS2 Regulates Ovarian Cancer Progression by Targeting miR-182-5p/FOXF2 Signaling Pathway |
External Links
| Links for ADAMTS9-AS2 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |